Novo Nordisk A/S Target of Unusually High Options Trading (NYSE:NVO)

Novo Nordisk A/S (NYSE:NVO) saw unusually large options trading activity on Tuesday. Investors bought 38,912 call options on the stock. This is an increase of 45% compared to the average volume of 26,924 call options.

Institutional Trading of Novo Nordisk A/S

A number of hedge funds and other institutional investors have recently bought and sold shares of NVO. Advisor OS LLC raised its position in shares of Novo Nordisk A/S by 0.6% in the 2nd quarter. Advisor OS LLC now owns 13,972 shares of the company’s stock valued at $1,994,000 after purchasing an additional 82 shares during the last quarter. Cascade Financial Partners LLC lifted its stake in Novo Nordisk A/S by 2.3% in the 2nd quarter. Cascade Financial Partners LLC now owns 3,801 shares of the company’s stock worth $543,000 after purchasing an additional 84 shares in the last quarter. Novare Capital Management LLC boosted its position in shares of Novo Nordisk A/S by 3.2% during the 3rd quarter. Novare Capital Management LLC now owns 2,727 shares of the company’s stock valued at $325,000 after acquiring an additional 85 shares during the last quarter. AA Financial Advisors LLC grew its stake in shares of Novo Nordisk A/S by 3.2% in the 2nd quarter. AA Financial Advisors LLC now owns 2,805 shares of the company’s stock valued at $400,000 after buying an additional 86 shares during the period. Finally, Steel Grove Capital Advisors LLC raised its position in shares of Novo Nordisk A/S by 2.3% during the 2nd quarter. Steel Grove Capital Advisors LLC now owns 3,790 shares of the company’s stock valued at $541,000 after buying an additional 86 shares during the period. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analyst Ratings Changes

Several analysts recently weighed in on NVO shares. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. Finally, BMO Capital Markets decreased their price objective on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research note on Thursday, October 17th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $144.50.

Novo Nordisk A/S Trading Up 2.5 %

NVO stock traded up $2.49 during midday trading on Tuesday, reaching $102.30. 4,202,128 shares of the company traded hands, compared to its average volume of 4,475,606. The firm has a market capitalization of $459.07 billion, a price-to-earnings ratio of 32.30, a P/E/G ratio of 1.31 and a beta of 0.42. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The business has a 50 day moving average of $117.94 and a 200-day moving average of $129.42. Novo Nordisk A/S has a 52-week low of $94.73 and a 52-week high of $148.15.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.